Oral Proteins and Peptides Market Anticipated To Experience Fast-Paced Growth, In Terms Of Development and Use of Protein Therapeutics

The Oral Proteins and Peptides Market is expected to grow at an average annual rate of 11.7% from 2022 to 2028, reaching $8,233 million by 2023. In 2016, linaclotide drug type ranked first in market share.

Therapeutic proteins and peptides are an important class of drugs that provide services to patients in need of new treatments. Approved oral protein and peptide drugs are known to treat a variety of clinical signs including diabetes, gastrointestinal disorders and hormonal disorders.

Key factors driving growth in the global oral protein and peptide market are increased collaboration efforts among pharmaceutical companies, the spread of chronic diseases, an increase in the elderly population, and oral protein and peptide-based drugs.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/378

However, the high costs associated with drug development and the low bioavailability of these drugs hamper market growth. Conversely, an increase in new indications for known oral protein therapeutics, a high R & D investment by pharmaceutical companies for oral proteins and peptide drugs, and an increase in purchasing power in emerging markets are expected to provide manufacturers with a favorable opportunity.

The report provides extensive competitive analysis and profiles of key market players, such as
• Allergan plc
• AstraZeneca plc
• Biocon Limited
• Chiasma Inc.
• Proxima Concepts Limited (Diabetology Ltd.)
• Generex Biotechnology Corp.
• Novo Nordisk A/S
• Synergy Pharmaceuticals Inc.
• Tarsa Therapeutics Inc.

Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.

Gastrointestinal digestion applications have generated the highest revenue in 2016 and are expected to continue to do so in the future. This is due to the approval and adoption of oral protein and peptide drugs, LINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.). Diabetes applications are expected to grow at a CAGR of 13.4% between 2022 and 2028.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/378

The United States has a high prevalence of chronic diseases, an increased adoption rate of this drug, and an increased awareness of oral protein and peptide therapeutics, leading to market share in 2016. The world is expected to grow because of the rapid industrialization of the world economy, increased disposable income, and increased government initiatives to modernize medical infrastructure.

Key Findings of the Oral Proteins and Peptides Market:
• The insulin drug type segment is anticipated to grow at the highest CAGR from 2022 to 2028
• The gastric & digestive disorder application segment is anticipated to occupy the largest share in the oral proteins and peptides market
• The diabetes segment is expected to witness the highest growth rate during the forecast period
• The U.S. dominated the oral proteins and peptides market, and is projected to grow at a CAGR of 11.7%

Access Full Summery @ https://www.alliedmarketresearch.com/oral-proteins-peptides-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.